I think theres a huge market for these types of medicines. The U.S

When cagrilintide dosage with retatrutide questions arise: Appropriate Responses: Acknowledge that these are investigational compounds without approval for fitness applications Emphasize that no combination protocols exist in published research Redirect focus to evidence-based nutrition and training approaches that complement any medical interventions Suggest clients consult qualified medical professionals for peptide therapy decisions Provide education about realistic expectations and potential side effects Training Considerations: Clients using potent appetite suppressants like cagrilintide or retatrutide may experience: Reduced energy availability requiring modified training intensity Increased fatigue necessitating longer recovery periods Potential muscle loss if protein intake becomes inadequate Hydration challenges from GI side effects Programming should account for these factors, with emphasis on adequate nutrition, progressive overload appropriate to energy status, and careful monitoring of performance metrics

Racial, ethnic, and socioeconomic inequities in glucagon-like peptide-1 receptor agonist use among patients with diabetes in the US
Any use outside of a supervised clinical trial setting would be inappropriate and potentially unsafe
The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: The SURPASS clinical trials
Having said that, some patches may contain unlisted or undeclared ingredients, since they sit outside MHRA regulatory oversight as medicines